Valor Backs Genomics SaaS Platform Allelica
Summary
Says Peat, “Allelica brings precision medicine into mainstream clinical practice through a Software-as-a-Service platform for the prediction of complex, genetic diseases using proprietary polygenic risk scores. For example, in cardiology, Allelica has partnered with a leader in therapies for Coronary Artery Disease, Merck, to develop data-driven cardiovascular disease-risk stratification tools based upon Allelica’s polygenic risk scores for Coronary Artery Disease.” Allelica’s co-founders include two of the world’s leading genomic bioinformaticians and Polygenic Risk Score (PRS) scientists, CEO Giordano Bottà, Ph.D. and Chief Science Officer, George Busby, Ph.D., plus data scientist Paolo Di Domenico, Ph.D. Their fundamental research contributions helped develop the algorithms and AI that make genomic analysis possible at scale. Bottà says, “The Valor team brings decades of experience investing at seed stage in healthcare information technology and informatics in Allelica’s largest market, North America.” Allelica uses genomic data to stratify individuals with different trajectories of disease risk. This offers the potential to complement and improve conventional risk prediction and clinical practices in specialties and subspecialties such as fertility, cardiology, oncology, pediatrics, neurology, and more. Our mission is making inclusion the new normal in venture capital because diverse teams and boards produce premium returns.